A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?

Leukemia Research

Volumn 38, Issue 2, 2014, Pages 263-266

  Hasselbalch, Hans C ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Chronic inflammation; Experimental inflammation model; Human inflammation model; IL 1beta; IL 6; IL 8; Myeloproliferative neoplasms; NF E2 overexpression; NF kappabeta activation; Reactive oxygen species (ROS); TNF alpha

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 8; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NF E2; NFE2 PROTEIN, MOUSE; TRANSCRIPTION FACTOR NF E2 P45 SUBUNIT;

CHRONIC INFLAMMATION; CLONAL EVOLUTION; CYTOKINE PRODUCTION; ERYTHROCYTOSIS; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HEMOLYSIS; HUMAN; IN VIVO STUDY; LETTER; LEUKOCYTE ACTIVATION; LEUKOCYTOSIS; MYELOFIBROSIS; NONHUMAN; OXIDATIVE STRESS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTHEMIA; THROMBOCYTOSIS; TRANSACTIVATION; ANIMAL; CHRONIC DISEASE; DISEASE MODEL; GENETICS; INFLAMMATION; MOUSE; MYELOID METAPLASIA; PHYSIOLOGY;

ANIMALS; CHRONIC DISEASE; CLONAL EVOLUTION; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MICE; NF-E2 TRANSCRIPTION FACTOR, P45 SUBUNIT; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84892530527     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.07.002     Document Type: Letter

References (23)

1. Hasselbalch H.C. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?. Blood 2012, 119(14):3219-3225.
2. Hasselbalch H.C. Chromic inflammation as a promoter of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?. Leuk Res 2013, 37(2):214-220.
3. Hasselbalch H.C. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 2013 February, [Epub ahead of print].
4. Kaufmann K.B., Gründer A., Hadlich T., et al. A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J Exp Med 2012, 209(1):35-50.
5. Chuen C.K., Li K., Yang M., et al. Interleukin-1beta up-regulates the expression of thrombopoietin and transcription factors c-Jun, c-Fos, GATA-1, and NF-E2 in megakaryocytic cells. J Lab Clin Med 2004, 143(2):75-88.
6. Goerttler P.S., Kreutz C., Donauer J., et al. Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2. Br J Haematol 2005, 129(1):138-150.
7. Mutschler M., Magin A.S., Buerge M., et al. NF-E2 overexpression delays erythroid maturation and increases erythrocyte production. Br J Haematol 2009, 146:203-217.
8. Kim J., Cha Y.N., Surh Y.J. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat Res 2010, 690(1-2):12-23.
9. Ferguson L.R. Chronic inflammation and mutagenesis. Mutat Res 2010, 690:3-11.
10. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
11. Barbui T., Carobbio A., Finazzi G., et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 2011, 96(2):315-318.
12. Landolfi R., Di Gennaro L. Pathophysiology of thrombosis in myeloproliferative neoplasms. Haematologica 2011, 96(2):183-186.
13. Aumann K., Frey A.V., May A.M., et al. Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates pre-fibrotic primary myelofibrosis from essential thrombocythemia. Blood 2013 May, [Epub ahead of print].
14. Motohashi H., Kimura M., Fujita R., et al. NF-E2 domination over Nrf2 promotes ROS accumulation and megakaryocytic maturation. Blood 2010, 115:677-686.
15. Marty C., Lacout C., Droin N., et al. A role for reactive oxygen species in JAK2(V617F) myeloproliferative neoplasm progression. Leukemia 2013 April, [Epub ahead of print]. 10.1038/leu.2013.102.
16. Pellagatti A., Cazzola M., Giagounidis A., et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 2010, 24(4):756-764.
17. Skov V., Thomassen M., Riley C.H., et al. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp Hematol 2012, 40(9):771-780.
18. Skov V., Larsen T.S., Thomassen M., et al. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res 2012, 36(11):1387-1392.
19. Tsai J.J., Dudakov J.A., Takahashi K., et al. Nrf2 regulates haematopoietic stem cell function. Nat Cell Biol 2013, 15(3):309-316.
20. Wehrle J., Seeger T.S., Schwemmers S., et al. Transcription factor Nuclear Factor Erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms. Haematologica 2013 February, [Epub ahead of print].
21. Bogeska R., Pahl H.L. Elevated nuclear factor erythroid-2 levels promote epo-independent erythroid maturation and recapitulate the hematopoietic stem cell and common myeloid progenitor expansion observed in polycythemia vera patients. Stem Cells Transl Med 2013 February, 2(2):112-117.
22. Hole P.S., Darley R.L., Tonks A. Do reactive oxygen species play a role in myeloid leukemias?. Blood 2011, 117(22):5816-5826.
23. Jutzi J.S., Bogeska R., Nikoloski G., et al. MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. J Exp Med 2013 April, [Epub ahead of print].